The modern paradigm in the treatment and prevention of cardiovascular diseases using the polycapsule strategy | Ukrainian Medical Journal

Cardiovascular diseases the leading cause of death worldwide, and the trend is increasing due to the aging population. Low- and middle-income countries are particularly affected by this phenomenon due to insufficient control over risk factors. Taking multiple medications at the same time (polypharmacy) is a common problem that leads to low patient adherence to treatment, especially among the elderly. The use of polypills (capsules containing several active ingredients) helps to improve patient adherence to treatment due to a simplified dosing regimen and a reduction in the number of medications required. A number of clinical studies have confirmed the effectiveness of the polypill strategy for the treatment and prevention of cardiovascular diseases, particularly in reducing the risk of cardiovascular death and improving adherence to treatment. In Ukraine, polypills manufactured using Multiple Unit Dosage Form technology were first introduced by pharmaceutical company Microkhim. This technology provides high dosage uniformity and allows avoiding the pharmaceutical interaction of ingredients in the finished dosage form.

References

1. World Heart Federation. World Heart Report 2023: Confronting the World’s Number One Killer. Geneva, Switzerland.
2. Chong B., Jayabaskaran J., Jauhari S.M. et al. (2024) Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur. J. Preventi. Cardiol., 281. doi.org/10.1093/eurjpc/zwae281.
3. Jeemon P., Séverin T., Amodeo C. et al. (2021) World Heart Federation Roadmap for Hypertension — A 2021 Update. Glob. Heart, 16(1): 63. DOI: 10.5334/gh.1066.
4. Ray K.K., Ference B.A., Séverin T. et al. (2022) World Heart Federation Cholesterol Roadmap 2022. Glob. Heart, 17(1): 75. DOI: 10.5334/gh.1154.
5. The World Heart Federation, Severin T., Champagne B. et al. (2022) World Heart Vision 2030: Driving Policy Change. Geneva, Switzerland.
6. Laranjo L., Lanas F., Sun M.C. et al. (2024) World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update. Glob. Heart, 19(1): 8. doi: 10.5334/gh.1278.
7. http://www.ukrinform.ua/rubric-ato/3834086-sercevosudinni-zahvoruvanna-e-najposirenisou-pricinou-peredcasnoi-smerti-ukrainciv-eksperti.html.
8. de Abreu-Silva E.O., Siepmann M., Siepmann T. (2024) Polypills in the Management of Cardiovascular Risk — A Perspective. J. Clin. Med., 13: 5487.
9. Muntner P., Hardy S.T., Fine L.J. et al. (2020) Trends in blood pressure control among US adults with hy- pertension, 1999–2000 to 2017–2018. JAMA, 324: 1190–1200.
10. WHO Newsroom-Fact Sheets–Detail–Hypertension. http://www.who.int/news-room/fact-sheets/detail/hypertension.
11. Zgouro P., Katsamenis O.L., Moschakis T. et al. (2024) A floating 3D printed polypill formulation for the coadministration and sustained release of antihypertensive drugs. Int. J. Pharm., 655: 124058. doi: 10.1016/j.ijpharm.2024.124058.
12. Perel P., Avezum A., Huffman M. et al. (2015) Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Glob. Heart, 10: 99–110.
13. Dharmagadda S. (2023) Fixed-Dose Combinations: Innovations and Research. In: P.P. Singh (Eds.) Recent Advances in Pharmaceutical Innovation and Research. Springer, Singapore.
14. Di Fusco S.A., Aquilani S., Spinelli A. et al. (2023) The polypill strategy in cardiovascular disease prevention: It’s time for its implementation. Prog. Cardiovasc. Dis., 79: 37–40.
15. Birla S., Angural A., Madathumchalil A. et al. (2023) Redefining the polypill: pros and cons in cardiovascular precision medicine. Front. Pharmacol., 14: 1268119.
16. Hu J., Wan J., Xi J. et al. (2024) AI-driven design of customized 3D-printed multi-layer capsules with controlled drug release profiles for personalized medicine. Int. J. Pharm., 656: 124114. doi: 10.1016/j.ijpharm.2024.124114.
17. Sarfo F.S., Adu-Gyamfi R., Opare-Addo P.A. et al. (2024) Effect of a Cardiovascular Polypill on Poststroke Cognition Among Ghanaians: Secondary Analysis of a Randomized Clinical Trial. J. Am. Heart Assoc., 13(15): e034346.
18. Yusuf S., Joseph P., Dans A. et al.; International Polycap Study 3 Investigators (2021) Polypill with or without Aspirin in Persons without Cardiovascular Disease. N. Engl. J. Med., 384(3): 216–228. doi: 10.1056/NEJMoa2028220.
19. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 Jun 28; 326(7404): 1419. doi: 10.1136/bmj.326.7404.1419.
20. Yusuf S., Attaran A., Bosch J. et al. (2014) Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur. Heart J., 35(6): 353–364.
21. Ibanez B., Castellano J.M., Fuster V. (2019) Polypill strategy at the heart of cardiovascular secondary prevention. Heart, 105(1): 9–10.
22. Whelton P.K., Carey R.M., Aronow W.S. et al. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71(6): e13–e115.
23. Fuster V., Gambús F., Patriciello A. et al. (2017) The polypill approach — An innovative strategy to improve cardiovascular health in Europe. BMC Pharmacol. Toxicol., 18(1): 10. doi: 10.1186/s40360-016-0102-9.
24. Gnanenthiran S.R., Tan I., Atkins E.R. et al. (2023) Transforming blood pressure control in primary care through a novel remote decision support strategy based on wearable blood pressure monitoring: The NEXTGEN-BP randomized trial protocol. Am. Heart J., 265: 50–58. doi: 10.1016/j.ahj.2023.07.005.
25. Muñoz D., Uzoije P., Reynolds C. et al. (2019) Polypill for Cardiovascular Disease Prevention in an Underserved Population. N. Engl. J. Med., 381(12): 1114–1123. doi: 10.1056/NEJMoa1815359.
26. Sukonthasarn A., Chia Y.C., Wang J.G. et al. (2021) The feasibility of polypill for cardiovascular disease prevention in Asian Population. J. Clin. Hypertens. (Greenwich), 23(3): 545–555. doi: 10.1111/jch.14075.
27. Patel A., Ojji D., de Silva H.A. et al. (2022) Polypills for the prevention of cardiovascular disease: a framework for wider use. Nat. Med., 28(2): 226–229.
28. Hummler H., Page S., Stillhart C. et al. (2024) Esophageal transit of solid oral dosage forms — impact of different surface materials characterized in vitro and in vivo by MRI in healthy volunteers. Eur. J. Pharm. Sci., 203: 106926.
29. Кравчун П.П., Дунаєва І.П. (2024) Сучасні підходи до подвійної антитромбоцитарної терапії у пацієнтів із високим серцево-судинним ризиком. Укр. мед. часопис, 2(160): umj.com.ua/wp/wp-content/uploads/2024/04/5422.pdf.
30. Bellini M., Walther M., Bodmeier R. (2019) Evaluation of manufacturing process parameters causing multilayer tablets delamination. Int. J. Pharm., 570: 118607.
31. Arockiam S., Staniforth B., Kepreotis S. et al. (2023) A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice. Int. J. Mol. Sci., 24(13): 11132.
32. Amarenco P., Denison H., Evans S.R. et al. (2020) Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke A J. Cereb. Circ., 51: 3504–3513.
33. Virk G.S., Sharma A., Khan M.R. et al. (2023) The Effectiveness of Polypill for the Prevention of Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Cureus, 15(10): e47032. doi: 10.7759/cureus.47032.
34. Bonaca M.P., Scirica B.M., Creager M.A. et al. (2013) Vorapaxar in patients with peripheral artery disease: Results from TRA2° P-TIMI 50. Circulation, 127: 1522–1529.
35. Yeh R.W., Secemsky E.A., Kereiakes D.J. et al. (2016) Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year after Percutaneous Coronary Intervention. JAMA, 315: 1735–1749.
36. Joseph P., Roshandel G., Gao P. et al. (2021) Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet, 398: 1133–1146.
37. Кравчун П.П. (2024) Новітні європейські рекомендації щодо менеджменту пацієнтів з артеріальною гіпертензією: огляд коментарів від провідних експертів. Здоров’я України, 4(95).
38. McEvoy J.W., McCarthy C.P., Bruno R.M. et al.; ESC Scientific Document Group (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J., 45(38): 3912–4018. doi: 10.1093/eurheartj/ehae178.
39. Liuzzo G., Patrono C. (2024) A SECURE polypill as a strategy at the heart of secondary prevention. Eur. Heart J., 43(43): 4534–4535. doi: 10.1093/eurheartj/ehac518.
40. Penson P.E., Banach M. (2024) Reaping the rewards of a simplified dosing regimen. Eur Heart J. Cardiovasc. Pharmacother., pvae073. doi: 10.1093/ehjcvp/pvae073.
41. Roshandel G., Khoshnia M., Poustchi H. et al. (2019) Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): A pragmatic, cluster-randomised trial. Lancet, 394: 672–683.
42. Mostaza J.M., Suárez-Fernández C., Cosín-Sales J. et al.; VULCANO Investigators (2022) Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: The international VULCANO randomised clinical trial. BMC Cardiovasc. Disord., 22: 560.
43. Omrani H., Bahremand M., Keshavarzi F. et al. (2023) Correlation of polypill and blood pressure level: A systematic review of clinical trials. J. Educ. Health Promot., 12: 171.
44. Pravin S., Sudhir A. (2018) Integration of 3D printing with dosage forms: A new perspective for modern healthcare. Biomed. Pharmacother., 107: 146–154.
45. Castellano J.M., Pocock S.J., Bhatt D.L. et al.; SECURE Investigators (2022) Polypill Strategy in Secondary Cardiovascular Prevention. N. Engl. J. Med., 387(11): 967–977.
46. Ragelle H., Rahimian S., Guzzi E.A. et al. (2021) Additive manufacturing in drug delivery: Innovative drug product design and opportunities for industrial application. Adv. Drug Deliv. Rev., 178: 113990. doi: 10.1016/j.addr.2021.113990.
47. Skylar-Scott M.A., Uzel S.G.M., Nam L.L. et al. (2019) Biomanufacturing of organ-specific tissues with high cellular density and embedded vascular channels. Sci. Adv., 5(9): eaaw2459. doi: 10.1126/sciadv.aaw2459.
48. Сиренко Ю.М. (2024) Фіксовані комбінації препаратів — основа сучасної антигіпертензивної терапії. Арт. гіперт. серцево-судинні захвор., 17(3): 5–6.
49. Mohd H., Rao N.G., Avanapu S. et al. (2013) Impact of capsules as a carrier for multiple unit drug delivery and the importance of HPMC capsules. Res. J. Pharm. Technol., 6: 34–43.
50. Настанова 42-7.3:2020 «Лікарські засоби. Дослідження біоеквівалентності». Київ, МОЗ України.
51. Настанова. Лікарські засоби. Належна клінічна практика. СТ-Н МОЗУ 42-7.0:2008 (зі змінами, внесеними згідно з наказом Міністерства охорони здоров’я України від 26.09.2017 р. № 1169).
52. Joseph P., Pais P., Dans A.L. et al.; TIPS-3 Investigators (2018) The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. Am. Heart J., 206: 72–79. doi: 10.1016/j.ahj.2018.07.012.